vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
Perella Weinberg Partners is the larger business by last-quarter revenue ($219.2M vs $139.2M, roughly 1.6× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 6.3%, a 29.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -2.9%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $30.5M). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
ADMA vs PWP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $219.2M |
| Net Profit | $49.4M | $13.8M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 8.5% |
| Net Margin | 35.5% | 6.3% |
| Revenue YoY | 18.4% | -2.9% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $219.2M | ||
| Q3 25 | $134.2M | $164.6M | ||
| Q2 25 | $122.0M | $155.3M | ||
| Q1 25 | $114.8M | $211.8M | ||
| Q4 24 | $117.5M | $225.7M | ||
| Q3 24 | $119.8M | $278.2M | ||
| Q2 24 | $107.2M | $272.0M | ||
| Q1 24 | $81.9M | $102.1M |
| Q4 25 | $49.4M | $13.8M | ||
| Q3 25 | $36.4M | $6.0M | ||
| Q2 25 | $34.2M | $2.7M | ||
| Q1 25 | $26.9M | $17.3M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $16.4M | ||
| Q2 24 | $32.1M | $-66.0M | ||
| Q1 24 | $17.8M | $-35.8M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 8.5% | ||
| Q3 25 | 38.0% | 5.4% | ||
| Q2 25 | 35.1% | 5.8% | ||
| Q1 25 | 30.4% | 5.5% | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | 12.9% | ||
| Q2 24 | 36.6% | -30.2% | ||
| Q1 24 | 26.7% | -52.4% |
| Q4 25 | 35.5% | 6.3% | ||
| Q3 25 | 27.1% | 3.6% | ||
| Q2 25 | 28.1% | 1.8% | ||
| Q1 25 | 23.4% | 8.2% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 5.9% | ||
| Q2 24 | 29.9% | -24.3% | ||
| Q1 24 | 21.7% | -35.1% |
| Q4 25 | $0.20 | $0.11 | ||
| Q3 25 | $0.15 | $0.08 | ||
| Q2 25 | $0.14 | $0.04 | ||
| Q1 25 | $0.11 | $0.24 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | $0.24 | ||
| Q2 24 | $0.13 | $-1.21 | ||
| Q1 24 | $0.08 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $255.9M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $-127.4M |
| Total Assets | $624.2M | $797.6M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $255.9M | ||
| Q3 25 | $61.4M | $185.5M | ||
| Q2 25 | $90.3M | $145.0M | ||
| Q1 25 | $71.6M | $111.2M | ||
| Q4 24 | $103.1M | $407.4M | ||
| Q3 24 | $86.7M | $335.1M | ||
| Q2 24 | $88.2M | $185.3M | ||
| Q1 24 | $45.3M | $156.7M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $-127.4M | ||
| Q3 25 | $431.2M | $-302.4M | ||
| Q2 25 | $398.3M | $-318.4M | ||
| Q1 25 | $373.4M | $-323.1M | ||
| Q4 24 | $349.0M | $-421.4M | ||
| Q3 24 | $231.9M | $-360.8M | ||
| Q2 24 | $188.3M | $-283.0M | ||
| Q1 24 | $153.7M | $161.9M |
| Q4 25 | $624.2M | $797.6M | ||
| Q3 25 | $568.7M | $650.2M | ||
| Q2 25 | $558.4M | $606.7M | ||
| Q1 25 | $510.6M | $570.5M | ||
| Q4 24 | $488.7M | $876.8M | ||
| Q3 24 | $390.6M | $810.9M | ||
| Q2 24 | $376.4M | $645.5M | ||
| Q1 24 | $350.9M | $583.6M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $34.8M |
| Free Cash FlowOCF − Capex | $34.6M | $30.5M |
| FCF MarginFCF / Revenue | 24.8% | 13.9% |
| Capex IntensityCapex / Revenue | 0.8% | 2.0% |
| Cash ConversionOCF / Net Profit | 0.72× | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $34.8M | ||
| Q3 25 | $13.3M | $59.2M | ||
| Q2 25 | $21.1M | $56.1M | ||
| Q1 25 | $-19.7M | $-176.5M | ||
| Q4 24 | $50.2M | $223.4M | ||
| Q3 24 | $25.0M | $200.3M | ||
| Q2 24 | $45.6M | $90.0M | ||
| Q1 24 | $-2.2M | $-206.3M |
| Q4 25 | $34.6M | $30.5M | ||
| Q3 25 | $-1.1M | $57.6M | ||
| Q2 25 | $18.7M | $55.3M | ||
| Q1 25 | $-24.4M | $-177.6M | ||
| Q4 24 | $47.5M | $207.0M | ||
| Q3 24 | $24.0M | $199.3M | ||
| Q2 24 | $43.6M | $83.7M | ||
| Q1 24 | $-4.6M | $-214.8M |
| Q4 25 | 24.8% | 13.9% | ||
| Q3 25 | -0.8% | 35.0% | ||
| Q2 25 | 15.3% | 35.6% | ||
| Q1 25 | -21.2% | -83.8% | ||
| Q4 24 | 40.4% | 91.7% | ||
| Q3 24 | 20.0% | 71.6% | ||
| Q2 24 | 40.7% | 30.8% | ||
| Q1 24 | -5.6% | -210.3% |
| Q4 25 | 0.8% | 2.0% | ||
| Q3 25 | 10.7% | 0.9% | ||
| Q2 25 | 2.0% | 0.5% | ||
| Q1 25 | 4.1% | 0.5% | ||
| Q4 24 | 2.3% | 7.3% | ||
| Q3 24 | 0.9% | 0.4% | ||
| Q2 24 | 1.9% | 2.3% | ||
| Q1 24 | 2.9% | 8.3% |
| Q4 25 | 0.72× | 2.52× | ||
| Q3 25 | 0.36× | 9.85× | ||
| Q2 25 | 0.62× | 20.50× | ||
| Q1 25 | -0.73× | -10.18× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 12.23× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PWP
Segment breakdown not available.
